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EDITORIAL Open Access
Rigor in science and science reporting:
updated guidelines for submissions to
Molecular Autism
Joseph D. Buxbaum1,2,3,4,5,6* , Simon Baron-Cohen7, Evdokia Anagnostou8,9, Chris Ashwin10, Catalina Betancur11,
Bhismadev Chakrabarti7,12, Jacqueline N. Crawley13, Rosa A. Hoekstra14, Patrick R. Hof1,4,5, Meng-Chuan Lai7,15,16,
Michael V. Lombardo7,17 and Cynthia M. Schumann13
There was some controversial press reporting of an
article published in Molecular Autism by Anwar et al.
[1]. In addition, at least two organizations dedicated
to scientific accuracy in reporting have commented
on this article, including www.sciencemediacentre.org
and www.healthnewsreview.org. While the authors
expressed some of the caveats of the study in their
article, the subsequent reporting in the press and
non-specialist community omitted critical caveats and
we feel compelled to alter our guidelines to better ad-
dress such issues.
A particular concern is claims about a biological
test being diagnostic. Countless publications have
made the point that what is observed in a selected
sample of cases and controls is very far from being a
diagnostic test. Drs. Paul Meehl and Albert Rosen
summarized many of the relevant issues as early as
1955 [2], in response to a 1954 white paper by the
American Psychological Association [3]. In summary,
findings of even very significant differences in a given
measure between cases versus controls are not by
themselves sufficient to support the use of such a
measure for diagnosis. This is especially true for rare
events because for “any attempt at prediction of infre-
quent behavior, a large number of false positives are
obtained” [4]. Even with an incidence of around 1%,
autism would be considered such a rare event.
Researchers focusing on diagnostics are generally
aware of these issues and reviewing such issues is (or
should be) part of any good training program for cli-
nicians and for anyone involved in translational re-
search. While there have been many papers over the
ensuing 60 years that made these points, we will re-
view them once more in the current context.
The important terms to remember are sensitivity and
specificity. Sensitivity, in the context of autism diagno-
ses, is the proportion of individuals with autism that are
correctly identified as having autism. Specificity, in con-
trast, is the proportion of typical individuals who are
correctly identified as typical. The best classifier identi-
fied by Anwar et al. had a sensitivity of 0.92 and a speci-
ficity of 0.84.
While these numbers are quite intriguing, the re-
sults in Anwar et al. are derived from a sample that
is maximally 31 typical individuals and 39 individuals
with autism. In other words, the sample size was ex-
ploratory and, most importantly, 55% of the individ-
uals in the study have an autism diagnosis, compared
to approximately 1% in the general population. Here,
we consider how the same sensitivity and specificity
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plays out in a population sample (i.e., assuming 99%
of the sample population is typically developing).
As can be seen from the Table, in a more representative
sample, using the same sensitivity and specificity measures
but with a base rate of 1%, fully 95% (602 out of 637) of
individuals in the population receiving an autism label
based on the screen would not have autism. In addition,
under both scenarios, 8% of individuals with autism would
be misclassified.
There are some scenarios where such a high false-positive
rate might be acceptable, for example, where the burden is
small, the outcome dire, and immediate treatment with an
effective intervention is critical to changing the outcome
(e.g., neonatal screening for treatable metabolic disorders).
However, it would be hard to argue for such a test in aut-
ism where we have reasonable tools for diagnosis and the
effective interventions are both costly and can be adminis-
tered over a larger temporal window.
Moreover, this remains a most optimistic scenario.
For example, we have no idea how other conditions
may test using this screen and the authors appropri-
ately call for an “assessment of the specificity of the
algorithms for autism versus other psychiatric condi-
tions.” And note that for some measures in the
Anwar et al. study [1], the numbers of typical and
autism subjects were lower (e.g., 21 vs 27 for the me-
tabolite that was associated with the best classifier).
In addition, the sensitivity and specificity were chosen
as the best from multiple different algorithms and from
multiple different tests, without formal correction for
experiment-wide error, and replication of such findings is
a sine qua non for advancing any potential screen or even
any scientific findings. This is especially true for a condi-
tion that is as etiologically and clinically heterogeneous as
autism. Again, the authors make this clear in their
Conclusions, where they note: “For future studies, we
suggest firstly validation of the current findings in an inde-
pendent clinical study group.” With validation in an
independent sample and prospective studies of, for
example, high-risk individuals, together with studies in
other neurodevelopmental conditions, we may begin to
have another clue into the biology of autism. But likely
not a diagnostic test.
This nuance and cautious reporting by the authors
was not always well reflected in reports in the press.
Here are two out of several examples: “Blood test which
is 90% accurate could help to diagnose autism in chil-
dren by detecting early warning signs” (Daily Mail); and,
“The most reliable of the tests is better than any other
diagnostic method available” (Newsweek).
Many of the relevant news reports do not include any
feedback from experts. When they do, they are much
more balanced. CNN, for example, noted that “experts
caution that the tests are far from becoming available
clinically and that more research needs to be done.” And
they include opinions from individuals not involved in
the study. Dr. James Cusack is quoted as saying that,
“This (study) is weakened by a small sample size, pos-
sible overfitting of data and a lack of comparison
groups,” and that, “This study does not tell us how ef-
fectively this measure can differentiate between autism
and other neurodevelopmental or mental health condi-
tions such as ADHD and anxiety.”
And CNN goes on to quote Dr. Max Davie, a spokes-
man for the Royal College of Paediatrics and Child
Health: Dr. Davie notes that “This is a promising area;
however, this is a very long way indeed from a test for
autism,” and that, “It is important that it is not adopted
with too much enthusiasm. If applied to a large popula-
tion, it will produce large number of false positives,
causing huge worry and potential harm to children and
families.”
As scientists who have worked in the field of autism re-
search for decades and have learned the importance of al-
ways putting families first, we need to protect against the
risk of scientific inaccuracy by emphasizing limitations
and caution, to maximize the accuracy of public summar-
ies of any study. Molecular Autism prides itself on being
open access and we hope that our papers are accessible to
families and to non-experts. The upshot of this must be
that the Editors-in-Chief, Associate Editors, reviewers,
and BMC staff do everything we can to give an honest ap-
praisal of impact in every paper, no matter how redundant
the cautions may be.
As Editors, in relation to the Anwar et al. study [1],
we should have insisted that any mention of diag-
nostics should have been minimized in the publica-
tion and the limitations be explicitly addressed.
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Although the authors and the expert reviewers were
clearly aware of the limitations, we should have em-
phasized and re-emphasized them in the publication.
As a second link in the chain we note that, in many ex-
amples of press surrounding the study by Anwar et al. [1],
the text in print and online news was taken from a univer-
sity press release. There is evidence that a source of exag-
geration of research findings in the news can result from
exuberant press releases from both universities and jour-
nals [5, 6]. Importantly, these same studies show that nei-
ther exaggerated claims nor caveats included in press
releases overly influence the likelihood of news coverage,
so being more cautious does not come at any real cost to
the authors, their universities, or to the journal. It is the
responsibility of authors and editors to work with institu-
tional and journal press offices and ensure that caveats are
clear and exaggerated claims are minimized.
The third link in the chain is that of the news organi-
zations themselves. Ideally, these organizations should
carry out critical reporting on news stories, which in-
cludes getting feedback from experts not involved in
the work. In some cases, this can be done with little ef-
fort. For example, the quotes from Drs. Cusack and Da-
vie come directly from the Science Media Centre, a
group that solicits expert comments in order to help
journalists understand and cover stories accurately
(http://www.sciencemediacentre.org/expert-reaction-to-
blood-and-urine-biomarkers-for-autism/). The Science
Media Centre sends these quotes directly to the press
before the embargo is lifted and journalists often use
these quotes in their reports.
Additionally, the American Association for the Ad-
vancement of Science has developed SciLine (https://
www.sciline.org). SciLine connects scientists and
journalists to help ensure that scientific principles and
evidence are conveyed accurately and in proper perspec-
tive (the name SciLine blends “science” and “deadline,”
to emphasize the need for rapid, accurate responses
from scientist volunteers).
HealthNewsReview.Org dissects some health claims in
the popular press and commented on a report in the
Guardian press around Anwar et al. as well. They note
that “the story lifts quotes and almost entire sentences
from a news release with no apparent original reporting.”
In addition they remark that: “What would have helped
this story considerably would be interviewing sources not af-
filiated with the study to clarify the limitations of these bio-
markers, explain how autism is currently diagnosed, and
provide some much-needed context about the novelty, avail-
ability, and clinical relevance of the biomarkers studied”
(https://www.healthnewsreview.org/review/guardian-trumpe
ts-test-diagnose-autism-wheres-evidence/).
To their credit, in response to this criticism, the
Guardian posted a few days later a note with a
statement from the UK autism research charity,
Autistica: “This is a small, early-stage study which
may explain one biological difference in autism. At
this stage, the results presented are not strong
enough to suggest that this method could be used for
the diagnosis of autism. For example, we don’t know
whether this technique can distinguish autism from
ADHD, anxiety or other similar conditions. There
have been many previous attempts to develop a bio-
logical test for autism. Still, the best way to diagnose
autism is through clinical interview and observation,
which takes into account the many features of
autism.”
We are therefore instituting some additional steps
in our publication process to help ensure that we
minimize the gap between what is presented in our
journal and what is reported in the larger community.
First, we require a description of limitations. In
addition, we feel that the expectations that are universal
for basic science must also be applied to participant
based research. In an Editorial on genetics we noted that
(1) suitable (i.e., large) sample sizes, (2) small P values
including correction for multiple testing, (3) confirma-
tory replication studies, and (4) estimates of effect size
are required for any such submission to Molecular
Autism [7]; these guidelines will now be applied more
broadly as detailed below. We also ask that attention be
paid to press around articles. These changes are enumer-
ated here.
1. Limitations
Every article must now include an explicit
Limitations section. Articles without this will not
be reviewed and the handling editors and reviewers
will be asked to review and evaluate this section
carefully.
2. Sample size
While, in the past, sample sizes of thousands
seemed unattainable for genetics and then for
imaging, in both cases, these have been achieved
in autism. For blood and urine tests, we would
expect that, in any submission to Molecular
Autism, the discovery set have over 200 subjects
and that the replication sample be of a similar
size. For other studies, optimal sample sizes are
not always attainable or even defined. For
example, there are only modest numbers of
postmortem brains for autism. Similarly, a study
of a rare genetic disorder may include only a
modest number of participants. We would still
welcome such studies, recognizing, for example
with postmortem studies, that the results with
larger samples may overturn prior results as
recently happened in schizophrenia [8]. Such
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issues would now be presented in the Limitations
section.
3. P values
There is a significant body of empirical and
theoretical data that raises questions about the
meaning of a nominal P < 0.05. A very large number
of papers have recently addressed possible solutions
to the issues of P values ([9], together with over 20
co-publications in the same issue; [10, 11]). Benja-
min et al. [10] (which included over 70 experts)
suggested lowering P value thresholds to 0.005.
While we will continue to consider manuscripts
with more modest P values, a frank discussion of
the careful interpretation of such values should ap-
pear in Limitations. Of course, some important,
negative studies will not have significant P values,
and such studies are welcome.
4. Replication samples
In biochemical, molecular genetic, cell and animal
studies, there is now a universal expectation of both
suitably powered studies and replication. Why
should participant-based research, with the burden
it necessarily places on families, and with the ex-
treme heterogeneity of autism, be held to a lower
standard? We expect to see a replication of any sig-
nificant, primary finding in all manuscripts.
5. Effect size
In genetics (and in meaningful clinical trials and meta-
analyses), the effect sizes of the major findings are
reported.We requested this in our prior editorial
directed at genetic studies [7] and we now require it
for all studies. Note that as data sets get larger, it is
easier and easier to have lower P values.
Whether these low P values are meaningful
either scientifically or clinically can only be
assessed by the inclusion of effect sizes for
primary results. Genetic or other -omics studies
with very low P values may have effect sizes that
are simply too small to be useful. For these
studies and for smaller studies, including effect
size, with confidence intervals, will aid in
interpretation. Another important approach is
sensitivity power analyses. Borrowing from the
new requirements for the Journal of Experimental




we ask that: “Each original empirical study with
existing data should report, for its key hypothesis
tests, a sensitivity power analysis” (available in
the free software program GPower http://
www.gpower.hhu.de/en.html), reviewers and
editors may then, “ask authors to justify why an
experiment only powerful enough to detect a
conventionally “large” or greater effect size was
run.” This is a useful and helpful approach and
aids in interpretation.
6. Press release
We would ask that authors carefully consider the
language in any press release and consider
coordinating press releases with the journal.
Coordinating press releases with the journal can
minimize discrepancies in message. This would also
avoid the awkward situation where the journal or its
Editors feel the need to respond to claims in the
press.
With these steps (i.e., a section on Limitations, appropri-
ate sample sizes, appropriate P value interpretation, effect
size and sensitivity power analysis, replication and validation
in an independent cohort, and attention to coincident
reporting by author institutions), applied to all studies in
Molecular Autism, we will ensure that we remain at the van-
guard of important and impactful research in autism, while
ensuring that reported findings and their potential impact
are understandable to the broadest audience.
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